N-[(2R,4R,5R)-2-[2-[2-[3-[2-[(2R,4R,5R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyethoxymethoxy]-2-methylpropoxy]ethoxy]ethoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[(2R,4R,5R)-2-[2-[2-[3-[2-[(2R,4R,5R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyethoxymethoxy]-2-methylpropoxy]ethoxy]ethoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
• 化学式: C₂₇H₅₀N₂O₁₆
• 分子量: 658.7
• InChiKey: HKSRCUXLPDYKOR-OVDKWVARSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4
• 重原子数：
  45
• 可旋转键数：
  21
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  253
• 氢给体数：
  8
• 氢受体数：
  16

文献信息

• ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20140179768A1

  公开（公告）日：2014-06-26

  The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
• COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
  申请人：ALNYLAM PHARMACEUTICALS, INC.

  公开号：US20150111841A1

  公开（公告）日：2015-04-23

  The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
• US9322018B2
  申请人：——

  公开号：US9322018B2

  公开（公告）日：2016-04-26
• US9631193B2
  申请人：——

  公开号：US9631193B2

  公开（公告）日：2017-04-25